FDA Accepts United Therapeutics' sNDA for Nebulized Tyvaso in IPF
UTHR sits 36% above its 52-week low of $375.61.
Summary
The FDA accepted United Therapeutics' supplemental New Drug Application for nebulized Tyvaso to treat idiopathic pulmonary fibrosis, with a review decision expected by late April 2027. The filing is backed by positive phase 3 TETON-1 and TETON-2 data showing a 111.8 mL improvement in forced vital capacity versus placebo (p<0.0001). This expands Tyvaso's potential label beyond PAH and PH-ILD into a large IPF market, addressing a key growth concern after Q2 revenue missed estimates due to Nebulized Tyvaso weakness. The acceptance follows the recent NDA acceptance for ralinepag, signaling a busy regulatory period for the company. A positive FDA decision would open a new revenue stream and could offset declining sales in the existing nebulized Tyvaso indication.
At the time of this announcement, UTHR was trading at $512.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $22B. The 52-week trading range was $375.61 to $609.35. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.